Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Exclusion Criteria

• •1. Histopathology confirmed a mixture of NSCLC and small-cell lung cancer
• •2. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •3. Prior malignancy within 5 years
• •4. History of organ transplantation or hematopoietic stem cell transplantation
• •5. Sever lung function decline or interstitial lung disease that has required oral or IV steroids
• •6. Active autoimmune disease requiring systemic therapy within 2 years
• •7. Immunodeficiency, or being treated with immunosuppressive therapy (including systemic glucocorticoid) within 7 days prior to the first dose of study treatment.
• •8. Active infections
• •9. Significant cardiac disorder
• •10. Other serious or uncontrolled systemic diseases assessed by the investigator.
• •Part A Dose escalation:
• •1\. Prior systemic therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or stimulatory or synergistic T-cell receptor (CTLA-4、OX-40、CD137) within 4 weeks
• •Part B Dose Expansion:
• •1. Any prior systemic anti-tumor therapy
• •2. Prior systemic immunotherapy, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or stimulatory or synergistic T-cell receptor (CTLA-4、OX-40、CD137)